Erchonia Donates Two High-Tech Lasers to Kent State

News Image

“With many people suffering from heel pain or toenail fungus, it’s important for our future doctors to understand what treatment options are out there and how Erchonia is making a difference.”

INDEPENDENCE, OH June 3, 2019 /PRNewswire/ –Erchonia Corporation, global leader in the manufacturing and development of low-level lasers, has donated two of its high-tech lasers to Kent State Podiatry College to be used at the university and at the Cleveland Foot & Ankle Clinics.

Kent State University College of Podiatric Medicine

Podiatry students will be able to use Erchonia’s FX 635 and Lunula Lasers in a clinical setting. This is the third podiatry college in the nation to have the opportunity to use these lasers. The first was the New York Podiatric College, and the second was Dr. William M. Scholl College of Podiatric Medicine in Chicago.

“We are honored to help give these students hands-on experience with our latest FDA cleared technologies,” says Steve Shanks, president of Erchonia Corporation. “With many people suffering from heel pain or toenail fungus, it’s important for our future doctors to understand what treatment options are out there and how Erchonia is making a difference.”

The FX635 Laser is used to treat both chronic lower back pain and chronic heel pain related to plantar fasciitis, and the Lunula Laser is used to treat onychomycosis (toe nail fungus). The Lunula Laser is the first and only non-thermal, “cold” laser to receive FDA market clearance for onychomycosis.

“The college is excited to partner with Erchonia Corporation and include this technology in our Cleveland Foot & Ankle Clinics to educate our students and treat patients,” said Dr. Allan Boike, Dean and CEO of Kent State University College of Podiatric Medicine. “As the leader in low level laser therapy, we look forward to providing alternative treatment modalities for patients suffering from chronic heel pain and inflammation, as well as onychomycosis. Our goal is to work with our faculty and students to initiate clinical trials and provide better patient care options.”

About Erchonia Corporation
Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. With 14 different market clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit www.erchonia.com.

Trevor Berry, DC, DACNB to Discuss Erchonia’s Low Level Laser Technology for Pain Treatment at the 2019 Arizona Association of Chiropractic Annual Convention on Friday, June 7

PHOENIX, June 3, 2019 /PRNewswire/ — Trevor Berry, DC, DACNB today announces he will be presenting at the upcoming 2019 Arizona Association of Chiropractic Annual Convention on Friday, June 7 at 2:00 p.m. at the Black Canyon Conference Center in Phoenix. During his session, he will discuss Erchonia’s low level laser technology and in particular its FDA clearances to market its ability to treat chronic lower back pain, chronic neck and shoulder pain and heel pain from plantar fasciitis — all without using drugs or invasive surgeries.

Dr. Berry comments, “I am thrilled to be presenting at Arizona Association of Chiropractic Annual Convention. I am excited to share more information about low-level laser technology and how it’s been proven to significantly treat pain in a variety of ways. It’s helped me treat patients more effectively in my practice based in Chandler.”

“We are very excited by the growth that we are achieving across the world,” adds Charlie Shanks, VP of Erchonia. “We are confident Erchonia lasers will continue to prove to be the prominent choice for those seeking laser therapy. Dr. Berry is an impeccable speaker who steadfastly continues to increase the understanding of laser therapy. His presentation in Phoenix will be second to none.”

Erchonia relies on double-blind, randomized, multi-site and placebo-controlled clinical trials in order to secure FDA market clearances for its low-level laser technology.

For more information about Dr. Berry, please visit www.azchironeuro.com or call (480) 756-2600. For more information on Erchonia, please visit www.erchonia.com.

About Erchonia Corporation
Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low-level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. With 14 different market clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit www.erchonia.com.

Erchonia’s Lunula Laser Gains Traction in Korean Market

News Image

“It’s very helpful for patients to have a non-thermal, painless treatment, covered by insurance. Doctors also save time with an effective and comfortable procedure for patients. The mutual needs of both doctors and patients are met with Lunula.”

Melbourne, Fla., May 21, 2019 — Erchonia Corporation, the global leader in low-level laser technology (“3LT”), is announcing new strides in the Korean market, particularly with its Lunula Laser, which targets foot fungus non-thermally and non-invasively with low-level laser technology. Since bringing its first Lunula unit to Korea back in 2015, Erchonia has continued to grow its stake there, placing a total of 277 units to date throughout the country.

The Lunula Laser is backed by extensive clinical data that led to the U.S. FDA market-clearing the laser to provide clear nail growth in patients with onychomycosis. In a placebo-controlled, randomized, double-blind clinical trial, 89 percent of patients responded to treatment, seeing clear, healthy nail growth in as little as four, 12-minute treatments per foot.

After Erchonia secured U.S. market clearance for the Lunula Laser, Erchonia’s international partner, C.M. Blue, registered the Lunula in Korea as the first device to improve onychomycosis with a non-thermal, low-level laser. Thanks to Lunula’s clinical results and Erchonia’s patent, C.M. Blue received approval from the Ministry of Food and Drug Safety (MFDS) on July 24, 2017, and Lunula has been growing in popularity in Korea ever since.

“The Lunula has been a great success among our product lines,” says Hoon Cheol Kim, CEO & President of C.M. Blue. “It’s very helpful for patients to have a non-thermal, painless treatment, covered by insurance. Doctors also save time with an effective and comfortable procedure for patients. The mutual needs of both doctors and patients are met with Lunula.”

C.M. Blue Sales & Marketing Director Joo Ho Park is also continuing this momentum by securing the most influential doctors to speak at medical conferences in Korea, targeting major clinics, and supporting Lunula’s expansion with various marketing activities including blogging and advertising.

About Erchonia Corporation
Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low-level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. With more than 15 clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit www.erchonia.com.

Opioid Alternative: Doctor Using Laser to Treat Lower Back Pain & Heel Pain

Fox

KRIV

May 13^th, 2019 Aired

Medical treatment of pain has typically involved NSAIDs, opioids or even surgery. Issues with effectiveness, side effects and addiction have fueled the demand for better pain management solutions. Dr. John Codwell, DPM of Houston, TX is a provider of the Erchonia FX 635 Laser. There are more than 3 million cases diagnosed in the U.S. per year who experience chronic heel pain or plantar fasciitis. Treatments for this pain usually include physical therapy, shoe inserts, steroid injections or surgery. However, these treatments are not always effective long-term.

Erchonia’s FX 635 is the first and only low-level laser to receive FDA market clearance for relief of chronic, musculoskeletal lower back pain and is also FDA-market cleared for chronic heel pain related to plantar fasciitis

The FX 635 low level laser treatments are pain-free, and you can immediately resume normal activities afterwards. When Erchonia says non-invasive, they mean it. Patients can’t even feel the laser.

Erchonia to Exhibit at 2019 Arab Health Conference in Dubai

News Image

“We are very excited by the growth that we are achieving across the world and are very much looking forward to Arab Health.”

Melbourne, Fla., January 10, 2019 — Erchonia Corporation, the global leader in low level laser therapy technology (“3LT”), today announces the company will be exhibiting at the upcoming 2019 Arab Health Conference at the Dubai World Trade Centre from January 28 to January 31.

Erchonia will share the latest from its non-invasive laser line including the FX 635, FDA market-cleared for chronic lower back pain and chronic heel pain from plantar fasciitis; the Verjú laser, FDA market-cleared for the circumferential reduction of the waist, hips and thighs, and the appearance of cellulite; and the LunulaLaser, FDA market-cleared for clear nail growth in patients with onychomycosis.

“We are very excited by the growth that we are achieving across the world and are very much looking forward to Arab Health,” says Charlie Shanks, VP of Erchonia Corporation.

“After a very successful 2018, we are delighted to continue our expansion,” adds Simon Ramshaw, managing director of UK-based Erchonia Lasers Ltd. “We now have representation in many new European markets and are looking to continue our rapid growth in 2019 and beyond.”

The low level laser technology Erchonia will be exhibiting at Arab Health is backed by extensive clinical data. In the placebo-controlled, randomized, double-blind clinical trial that led to the FX 635’s FDA market clearance, 72.4 percent reported at least a 30 percent decrease in their lower back pain with the laser treatment. Clinical trial data proved average pain reduction in patients of 58 percent. And Erchonia’s Verjú low level laser is the only device proven effective in a double-blind, multi-site, placebo-controlled study that delivered an average four-inch loss after two weeks of treatment. The FDA also cleared LunulaLaser when 89 percent of patients responded to treatment in a clinical trial, seeing clear, healthy nail growth in as little as four, 12-minute treatments per foot.

For more information on Erchonia, please visit www.erchonia.com.

About Erchonia Corporation

Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. With more than 15 clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit www.erchonia.com.

Good Day Bring Feet Out Of Hiding – Good Day Sacramento

Good Day Sacramento

Tina talks with Dr. Michael A. Uro the podiatrist and he has some tips on getting your feet in tip top shape for the summer!

Click Here to Play Video

Pain Infographic: Chronic Pain in Numbers

Chronic Pain is a major issue in society today that affects over 1.5 billion people around the world. This pain has proven to have detrimental effects on the overall quality of life.Erchonia also broke down some opioid epidemic stats in hopes to spread awareness and end the Opioid Epidemic with alternative methods, such as Erchonia Low Level Laser technology.

Chronic pain infographic

Erchonia & InnerScope Hearing Technologies to Conduct FDA Clinical Trial to Treat Tinnitus with Low Level Laser Technology

Erchonia Corporation today announces a joint development agreement with InnerScope Hearing Technologies to conduct clinical research and trials for the purpose of obtaining 510(k) clearances from the FDA for 3LT devices to treat hearing-related conditions, including tinnitus.

“We’re hopeful our partnership with InnerScope can make a real difference in patients’ lives and eventually provide a scientifically-proven, non-invasive option.”

Melbourne, FL (PRWEB) NOV 07, 2018

Erchonia Corporation, the global leader in the manufacturing and development of low level laser therapy technology (“3LT”), today announces a joint development agreement with InnerScope Hearing Technologies. Under the agreement, Erchonia and InnerScope will conduct clinical research and trials for the purpose of obtaining 510(k) clearances from the FDA for 3LT devices to treat hearing-related conditions, including tinnitus.

Erchonia and InnerScope expect to be the first to receive 510(k) clearance from the FDA for a treatment protocol for relief of tinnitus symptoms — not tinnitus “maskers” or management devices which are the only currently available options for patients. The companies have already received approval under FDA regulations from the Institutional Review Board for their initial clinical trial.

Commonly referred to as “ringing in the ears,” tinnitus is the perception of sound when no actual external noise is present. Approximately 20 percent of the world’s population suffers from tinnitus, experiencing buzzing, hissing, whistling, swooshing, or clicking. Those with intolerable tinnitus also often suffer from higher rates of anxiety, depression, low self-esteem, and poor quality of life.

“We’re looking forward to exploring low level laser’s impact on hearing disorders, especially on tinnitus, which can be debilitating,” says Steve Shanks, president of Erchonia Corporation. “We’re hopeful our partnership with InnerScope can make a real difference in patients’ lives and eventually provide a scientifically-proven, non-invasive option.”

For more information on the partnership, please visit https://www.erchonia.com.

About Erchonia Corporation

About InnerScope Hearing Technologies

InnerScope Hearing Technologies (INND) is a rapidly expanding consolidator of the hearing aid industry. Management is applying decades of profitable industry experience and technology to an antiquated and disjointed industry, unlocking scale and efficiency, which will serve all of InnerScope’s stakeholders. Its direct-to-consumer model is revolutionizing the industry with its Walmart.com relationship representing a paramount shift in the consumption of hearing aids by the hearing impaired. In addition InnerScope plans to continue to open, acquire, and operate a physical chain of audiological and retail hearing device clinics. InnerScope’s mission is to serve approximately 1.2 billion people around the globe that are suffering with 25 db or greater hearing loss across the entire hearing impaired vertical from R&D and manufacturing through direct consumer sales and services. For more information, please visit http://www.innd.com.

CBS’s “The Doctors” Showcases the Remarkable Lunula Laser as a Solution for Nail Fungus

Top-Rated Daytime Talk Show Features a Confident and Dramatic Patient Result

“We know our Lunula Laser can help so many people achieve healthy, clear nail growth without experiencing any harmful side-effects”

Melbourne, FL (PRWEB)October 22, 2018

Erchonia, the leading low-level laser technology manufacturer in the world today announces the company’s Lunula Laser was featured on an episode of CBS’s hit show “The Doctors” which aired on Friday, October 19th, 2018.

Board-certified dermatologist, Dr. Glynis R. Ablon, MD, discusses and demonstrates the Lunula Laser’s unique capacity to zap away toe nail fungus. While other treatment options provide unsuccessful, painful or harmful results in comparison to the FDA Market Cleared Lunula Laser. Toe nail fungus is not only a U.S. problem, but a world-wide problem. It is estimated that 10% of the world is plagued by this condition.

In contrast to high-power, high-heat lasers which have been used to treat toe nail fungus, the new Lunula Laser produces a low-level or cold output that is non-thermal with no effect on the body’s tissue or nail bed. Instead, the non-invasive Lunula Laser offers impressive clinical response stemming from its two therapeutic wavelengths: 405 nm (violet) and 635 nm (red). Each wavelength performs a very specific function to provide a comprehensive solution for toe nail fungus.

“We were so pleased with the patient’s results and think “The Doctors” segment is the perfect way to introduce the Lunula Laser to a national audience,” says Charlie Shanks, VP of Erchonia Corporation. “We know our Lunula Laser can help so many people achieve healthy, clear nail growth without experiencing any harmful side-effects.”

About Erchonia
A small family company is changing the world with the most advanced non-invasive lasers on the market. Erchonia went from starting in a small garage in 1996 to selling their products in over 50 different countries around the world in 2018. Erchonia has been passionate about researching and developing low level lasers since the beginning with over (14) FDA clearances for treating chronic pain and promoting fat loss. As this family has grown so has the world of non-invasive drug-free healthcare solutions

Erchonia Submits Data to US FDA to Support Low-Level Laser 510(k) Market Clearance for Autism

Quadruple-Blind laser study proves success in treating Autism in children and adolescents.

“The results are so strong, nobody can argue them.”

MELBOURNE, Fla. (PRWEB)September 05, 2018

Erchonia, the World Leader in Low Level Laser technology, announces today that they have submitted data to the US FDA to support a 510(k) market clearance for Autism.

The clinical trial was a quadruple-blind (Participant, Care Provider, Investigator and Outcome Assessor), randomized, placebo-controlled, and crossover clinical trial. The study was designed to treat autistic children with the 640nm Erchonia Spectrum Laser as the active device or a 640nm LED or light emitting diode as a placebo device, which had the same power output. FDA input was obtained prior to clinical trial and implemented into the protocol.

Both test and placebo patients were treated twice a week for 4 weeks. Post-treatment follow-up on both sets of patients was performed after 4 weeks, 8 weeks, and 6 months. At the end of 6 months, patients from the LED placebo group were crossed over and then given Erchonia’s Spectrum Laser treatment protocol. The results were documented and submitted to the US FDA for a 510(k) market clearance De Novo Application.

The inclusion criteria consisted of autistic children between the ages of 5 to 17 years old, and progress was measured by using the ABC or Aberrant Behavior Checklist as the primary diagnosis. The ABC 58-point symptom checklist was used to assess and classify behaviors of irritability and agitation; lethargy and social withdrawal, stereotypic behavior, hyperactivity and noncompliance, and inappropriate speech in children with developmental disorders. The ABC tests were performed at baseline, 2 weeks, and 4 weeks during the treatments phase, and 4 weeks, 8 weeks, and 6 months post-treatment in both the treated and placebo groups.

“This is a well-designed trial that shows evidence supporting the use of Low Level Laser Therapy in children and adolescents with autism,” said Dr. Morales-Quezada, Associate Research Director at Spaulding-Labushagne Neuromodulation Center. “Moreover, the technique proved to be safe and well tolerated by the study participants. The active intervention showed to be more effective than the placebo (sham) device in treating symptoms of autistic disorder, and this statistically significant treatment effect was observed for all clinical outcomes, by the end of the intervention period and after the 6 months follow-up. This evidence offers a new treatment option to be considered for children and adolescents with autism.”

Calixto Machado, MD, PhD, FAAN, President of the Cuban Society of the Clinical Neurophysiology Institute of Neurology and Neurosurgery agreed, “Results are so strong, nobody can argue them.”

Steven Shanks, President of Erchonia stated, “This study from a scientific perspective is one of the most stringent ways to perform a clinical trial. The original placebo patients have now acted as their own control group. The LED that was used as a placebo showed no results even though we used the same wavelength and power output.”

The Erchonia Spectrum Laser implemented in this clinical trial was a prototype laser and is not currently sold. While waiting for the 510(k) market clearance, Erchonia will start the development process for the new Erchonia Spectrum Laser.

Erchonia would like to thank Calixto Machado, MD, PhD, FAAN, Mauricio Chinchilla, MD, Yanin Ferrer, MD, and the University of Havana for their dedication to research and helping Erchonia with its latest achievement.

About Erchonia. Erchonia created the low-level laser category in January 2002 when the FDA granted Erchonia the very 1st 510(k) market clearance for any low-level laser. This new study further sets Erchonia apart from its competitors based on their commitment to research and numerous 510(k) market clearances obtained through blind and controlled clinical trials.

Need more info? Contact us today.